WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

ATC level alterations

Previous ATC codeATC level nameNew ATC code
L01XY02pertuzumab and trastuzumabL01FY01
L01XY03nivolumab and relatlimabL01FY02
L04AA02muromonab-CD3L04AG01
L04AA10sirolimusL04AH01
L04AA13leflunomideL04AK01
L04AA18everolimusL04AH02
L04AA21efalizumabL04AG02
L04AA23natalizumabL04AG03
L04AA25eculizumabL04AJ01
L04AA26belimumabL04AG04
L04AA27fingolimodL04AE01
L04AA29tofacitinibL04AF01
L04AA31teriflunomideL04AK02
L04AA33vedolizumabL04AG05
L04AA34alemtuzumabL04AG06
L04AA35begelomabL04AG07
L04AA36ocrelizumabL04AG08
L04AA37baricitinibL04AF02
L04AA38ozanimodL04AE02
L04AA39emapalumabL04AG09
L04AA42siponimodL04AE03
L04AA43ravulizumab L04AJ02
L04AA44upadacitinibL04AF03
L04AA45filgotinibL04AF04
L04AA46itacitinibL04AF05
L04AA47inebilizumabL04AG10
L04AA49peficitinibL04AF06
L04AA50ponesimodL04AE04
L04AA51anifrolumabL04AG11
L04AA52ofatumumabL04AG12
L04AA53teprotumumabL04AG13
L04AA54pegcetacoplanL04AJ03
L04AA55sutimlimabL04AJ04
L04AA56deucravacitinibL04AF07
L04AA57ublituximabL04AG14
L04AA59avacopanL04AJ05
N05CM19suvorexantN05CJ01
N05CM21lemborexantN05CJ02

Last updated: 2023-12-15